The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2013 ACR/ARHP Annual Meeting: The Rheumatoid Arthritis Treatment Debate

2013 ACR/ARHP Annual Meeting: The Rheumatoid Arthritis Treatment Debate

December 1, 2013 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • Global Perspectives on Managing Rheumatoid Arthritis Addressed at the 2013 ACR/ARHP Annual Meeting
  • 2013 ACR/ARHP Annual Meeting: Researchers Explore Role of Pathogens, Quality of Care in Rheumatoid Arthritis
  • 2013 ACR/ARHP Annual Meeting: Genetic Research Yields Clues to Pathogenesis of Rheumatoid Arthritis, Psoriatic Arthritis
Explore This Issue
December 2013
Also By This Author
  • Artificial Intelligence Gives Rheumatologists an Assist
The RA Treatment Debate

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

What is freedom? It is first, the capacity to deliberate or to weigh alternatives.
—Martin Luther King, Jr.

SAN DIEGO—Across from the San Diego Convention center, running along a path from Market Street to PETCO Park next to the trolley line, is the Martin Luther King, Jr. promenade, a walkway interspersed with concrete slabs etched with sayings by Dr. King. I happened to walk by the concrete slab with the saying shown in the above epigram shortly after sitting in a session billed as, “The Great Debate: Biologics or Triple Therapy for the Treatment of Rheumatoid Arthritis,” here at the 2013 ACR/ARHP Annual Meeting, held October 26–30. [Editor’s Note: This session was recorded and is available via ACR SessionSelect at www.rheumatology.org.] During the session, the respective merits of biologics and triple therapy for the treatment of patients with rheumatoid arthritis (RA) were debated. James O’Dell, MD, and Ronald van Vollenhoven, MD, certainly fulfilled the billing as lively debaters, but in the end, the real news for the practicing rheumatologist is that they now have more good alternatives to weigh when deliberating on which treatment strategy works best for their patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

When asked who he thought “won” the debate, session moderator Eric Matteson, MD, chair of rheumatology and professor of medicine at the Mayo Clinic in Rochester, Minn., said, “I think that the big winners are our rheumatologists and patients, who now have carefully considered options for effective treatment.”

“In my view,” he continued, “the field is set to move to the next stage—namely, to determine from disease onset, and also at point of determination of the need to switch therapy, which therapy is most appropriate for which patient from a safety, efficacy, and cost standpoint.”

The debate, he said, highlighted for rheumatologists the practical issues they and their patients face daily and offered an insightful appraisal of the best current knowledge and clinical science for triple therapy and biologics.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Triple Therapy for RA

James R. O’Dell, MD, professor of internal medicine in the division of rheumatology at Nebraska Medical Center in Omaha, opened the debate by framing his advocacy of triple therapy for RA over biologics through two general, interrelated themes: 1) The importance of managing patients with a treat-to-target approach; and 2) The need to consider the high cost of biologics. Overall, he said that many patients will not need biologics if managed with a treat-to-target approach that incorporates the use of triple therapy for patients who need more aggressive treatment.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Meeting Reports, Rheumatoid Arthritis Tagged With: ACR/ARHP, Annual Meeting, Biologics, Rheumatoid arthritis, Treatment, triple therapyIssue: December 2013

You Might Also Like:
  • Global Perspectives on Managing Rheumatoid Arthritis Addressed at the 2013 ACR/ARHP Annual Meeting
  • 2013 ACR/ARHP Annual Meeting: Researchers Explore Role of Pathogens, Quality of Care in Rheumatoid Arthritis
  • 2013 ACR/ARHP Annual Meeting: Genetic Research Yields Clues to Pathogenesis of Rheumatoid Arthritis, Psoriatic Arthritis
  • 2014 ACR/ARHP Annual Meeting: Rheumatoid Arthritis Management Treatment Recommendations

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)